METASTATIC COLORECTAL ADENOCARCINOMA
Clinical trials for METASTATIC COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will che…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough colorectal cancer: experimental drug combo enters human testing
Disease control TerminatedThis early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Poop pills plus immunotherapy: new hope for colorectal cancer patients?
Disease control OngoingThis pilot trial tests whether giving fecal microbiota transplants (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help control metastatic colorectal cancer in patients who previously did not respond to immunotherapy alone. The study enrol…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo treatment may slow colorectal cancer spread
Disease control OngoingThis trial is for people with colorectal cancer that has spread to a few spots in the body but cannot be fully removed by surgery alone. After 3-4 months of standard chemotherapy, participants either continue chemotherapy alone or also receive local ablative therapy—such as surge…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: NA • Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Gut bacteria boost? new trial tests probiotics to help immunotherapy fight stubborn colorectal cancer
Disease control OngoingThis early-phase study tests whether adding Akkermansia probiotics to standard immunotherapy and chemotherapy can safely help patients with advanced colorectal cancer that hasn't responded to prior treatments. The trial enrolls 22 adults whose tumors are MSS/pMMR type, which typi…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: NA • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a simple injection before and after surgery keep colorectal cancer at bay?
Disease control OngoingThis study tests whether a drug called QBECO, given as a self-injection before and after liver surgery, can lower the chance of colorectal cancer coming back or spreading. About 115 adults with colorectal cancer that has spread to the liver will take part. They will inject the dr…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and bevacizumab helps people with a specific type of advanced colorectal cancer (RAS-mutant, MSS) live longer without their cancer growing. About 446 adults who have not had prior t…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Last-Resort cancer drug made available to patients with no alternatives
Disease control NO_LONGER_AVAILABLEThis expanded access program offers fruquintinib, a targeted cancer drug, to adults with metastatic colorectal cancer that has worsened after all standard treatments. Participants take the drug as a capsule daily for three weeks, then one week off. The goal is to provide access u…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough colon cancer: Triple-Drug attack shows promise
Disease control OngoingThis study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow t…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough colorectal cancer: drug combo shows promise
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for advanced colorectal cancer: experimental combo shows promise
Disease control OngoingThis study tests a new drug (HR070803) added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 participants will receive either the new combo or standard treatment. The goal is to…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cocktail aims to outsmart resistant colorectal cancer
Disease control OngoingThis early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for Tough-to-Treat colorectal cancer?
Disease control OngoingThis study tests a new drug called nelmastobart combined with the chemotherapy capecitabine in people with metastatic colorectal cancer that no longer responds to standard treatments. About 59 adults will receive the combination to see if it is safe and can slow cancer growth. Th…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase 2 trial tests two experimental immunotherapy drugs, botensilimab and balstilimab, alone or together, against standard chemotherapy in 234 people with metastatic colorectal cancer that has not responded to prior treatments. The goal is to see if these drugs can shrink t…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC